Platinum-based chemotherapy plus cetuximab in head and neck cancer.

By J. Vermorken, R. Mesía, F. Rivera, É. Remenár, A. Kawecki, S. Rottey, J. Erfán, D. Zabolotnyy, H. Kienzer, D. Cupissol and 8 more. New England Journal of Medicine, 2008

3,370 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Periodontics, Surgery

View Paper: https://www.semanticscholar.org/paper/cddf2cf71ed85307b2824e507836740958b8d0f0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

An update on larynx cancer (2017, background): “While a subgroup analysis of laryngeal cancer (about 25% of patients) did not demonstrate this benefit of adding cetuximab, the numbers were small, and it is difficult to draw any conclusions based on primary site.(124) In conclusion, for fit patients in whom response is paramount, the EXTREME regim”
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma (2011, background): “As discussed earlier, EGFR is overexpressed in many head and neck cancers and molecular therapies targeting the EGFR/AKT signaling cascade (such as cetuximab) have been shown to increase the therapeutic efficacy of standard platinum-based chemotherapy [16,17].”
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort (2016, background): “Patients with $ 1 event 70 (53) 8 (6) 4 (3)”
Mechanisms of receptor tyrosine kinase activation in cancer (2018, neutral): “cetuximab in lung cancer [181], panitumumab in colon cancer [182], cetuximab in head and neck cancer [183], trastuzumab and pertuzumab in breast cancer [184, 185].”
A community computational challenge to predict the activity of pairs of compounds (2014, background): “Compound synergy can be measured by multiple endpoints, including reducing or delaying the development of resistance to treatment 3 (for instance by abrogating the emergence of resistant clones 4–6 ), improving overall survival 7,8 or lowering toxicity by decreasing individual compound dose 9 .”
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. (2014, background): “The impetus for the study stemmed from strong previous phase III data showing that combining cisplatin or cetuximab concurrently with radiation improved PFS and OS of patients with locally advanced HNC(10,20) and that adding cetuximab to platinum-based chemotherapy improved OS of patients with recur”
Oral squamous cell carcinomas: state of the field and emerging directions (2023, background): “The antibody cetuximab has been shown to suppress the EGFR pathway and is approved for HNSCC treatment.(397) NVP-BEZ235 inhibits the PI3K/AKT/mTOR pathway to sensitize OSCC cells to infrared radiation and diminish their resistance to radiotherapy.”